Back to Journals » OncoTargets and Therapy » Volume 9
Original Research
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
9,414 | Dovepress* | 8,479+ | 955 | 9,434 | |
PubMed Central* | 935 | 234 | 1,169 | ||
Totals | 9,414 | 1,189 | 10,603 | ||
*Since 30 November 2016 |
Total mentioned | Delicious | Others | |||
---|---|---|---|---|---|
3 | 0 | 0 | 1 | 0 | 2 |
View citations on PubMed and Google Scholar